Nasdaq · Healthcare
NEOGEN CORP (NEOG)
As-reported financials and recent SEC filings for NEOGEN CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$894.7M
Net income
$-1.09B
Net margin
-122.1%
Diluted EPS
$-5.03
ROE
-52.7%
P/E (TTM)
—
Market cap
$2.09B
Debt / equity
0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $894.7M | $924.2M | $822.4M | $527.2M | $468.5M |
| Gross profit | $421.4M | $463.9M | $406.0M | $243.0M | $215.1M |
| Operating income | $-1.06B | $58.7M | $37.5M | $58.6M | $74.2M |
| Net income | $-1.09B | $-9.4M | $-22.9M | $48.3M | $60.9M |
| Diluted EPS | $-5.03 | $-0.04 | $-0.12 | $0.45 | $0.57 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
11-K2026-06-25
View on EDGAR →42026-06-04
View on EDGAR →1442026-06-03
View on EDGAR →1442026-05-29
View on EDGAR →SD2026-05-20
View on EDGAR →42026-05-19
View on EDGAR →SCHEDULE 13G/A2026-05-14
View on EDGAR →42026-05-05
View on EDGAR →Go deeper on NEOG
Search NEOGEN CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.